Salva R Yurista

List of Publications by Year
in descending order

15 papers	633 citations	1040056 9 h-index	996975 15 g-index
18 all docs	18 docs citations	18 times ranked	819 citing authors

#	Article	IF	Citations
1	SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. Journal of Lipid and Atherosclerosis, 2022, 11, 1.	3.5	25
2	Targeting Myocardial Substrate Metabolism in the Failing Heart: Ready for Prime Time?. Current Heart Failure Reports, 2022, 19, 180-190.	3.3	11
3	Magnetic resonance imaging of cardiac metabolism in heart failure: how far have we come?. European Heart Journal Cardiovascular Imaging, 2022, 23, 1277-1289.	1.2	2
4	Exercise-induced CITED4 expression is necessary for regional remodeling of cardiac microstructural tissue helicity. Communications Biology, 2022, 5, .	4.4	2
5	Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. Circulation: Heart Failure, 2021, 14, e007684.	3.9	87
6	ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca2+ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIΐ´. International Journal of Molecular Sciences, 2021, 22, 4427.	4.1	9
7	Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 77, 1660-1669.	2.8	111
8	The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. Pflugers Archiv European Journal of Physiology, 2021, 473, 1301-1313.	2.8	10
9	Ketone Bodies. Journal of the American College of Cardiology, 2021, 78, 1433-1436.	2.8	5
10	Ketone bodies for the failing heart: fuels that can fix the engine?. Trends in Endocrinology and Metabolism, 2021, 32, 814-826.	7.1	26
11	Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?. Cardiovascular Diabetology, 2020, 19, 5.	6.8	29
12	Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. Cardiovascular Drugs and Therapy, 2020, 35, 953-963.	2.6	4
13	Effects of Sodiumâ€“Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. Cardiovascular Drugs and Therapy, 2020, 34, 311-321.	2.6	10
14	Unraveling the Molecular Mechanism of Action of Empagliflozin in HeartÂFailure With Reduced Ejection Fraction WithÂorÂWithout Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	4.1	65
15	Sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin improves cardiac function in nonâ€diabetic rats with left ventricular dysfunction after myocardial infarction. European Journal of Heart Failure, 2019, 21, 862-873.	7.1	236